SCHEMBL509299

SCHEMBL509299

COc1ccc(-c2cc3ccc(C)cc3c(N)n2)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.45
DHFR P00374 2/20 0.43
TLR8 Q9NR97 1/20 0.43
HSP90AA1 P07900 3/20 0.40
HSP90AB1 P08238 2/20 0.40
DYRK1A Q13627 1/20 0.38
SYK P43405 1/20 0.38
ACHE P22303 1/20 0.38
NPC1 O15118 1/20 0.38
CYP11B1 P15538 3/20 0.37
CYP11B2 P19099 3/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA5A P35218 1/20 0.37
CA5B Q9Y2D0 1/20 0.37
NCF1 P14598 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL510241 0.89 DHFR (0.43) RAD52DHFRHSP90AA1HSP90AB1DYRK1A
SCHEMBL509700 0.89 RAD52 (0.48) RAD52DHFRTLR8HSP90AA1HSP90AB1
SCHEMBL509858 0.82 SYK (0.56) DYRK1ASYKNPC1KDM4EALDH1A1
SCHEMBL509124 0.79 NPC1 (0.47) RAD52DYRK1ASYKNPC1ALDH1A1
SCHEMBL509116 0.79 DHFR (0.46) RAD52DHFRHSP90AA1NPC1KDM4E
SCHEMBL509138 0.78 SCN2A (0.48) SYKACHENPC1KDM4EALDH1A1
SCHEMBL509476 0.77 HSP90AA1 (0.56) RAD52DHFRHSP90AA1HSP90AB1NPC1
SCHEMBL3828449 0.76 NPC1 (0.55) TLR8NPC1CYP11B1CYP11B2
SCHEMBL14500789 0.72 KDM4E (0.47) DHFRACHEKDM4EALDH1A1LMNA
SCHEMBL508363 0.72 CYP1A2 (0.50) DHFRACHENPC1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314123-B2 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof REXAHN PHARMACEUTICALS, INC. (US) 2012-11-20 US disclosed
EP-2423196-A1 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof Rexahn Pharmaceuticals, Inc. (US) 2012-02-29 EP disclosed
US-20120029012-A1 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF REXAHN PHARMACEUTICALS, INC. (US) 2012-02-02 US disclosed
US-8034829-B2 e.g. 3-(3-methoxyphenyl)isoquinolin-1-amine; antiproliferative and antigrowth agent; breast tumors, prostate tumors, colon tumors, ovary tumors, kidney tumors, pancreas tumors, glioblastoma and melanoma. REXAHN PHARMACEUTICALS, INC. (US) 2011-10-11 US disclosed
US-20080182871-A1 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof REXAHN PHARMACEUTICALS, INC. (US) 2008-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182871-A1 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof FANCD2, NRAS, CCND2 RAD52 542/4885DHFR 178/4885TLR8 2716/4885
US-20120029012-A1 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF FANCD2, NRAS, CCND2 RAD52 542/4885DHFR 178/4885TLR8 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.